Meredith A.Stewart

Associate

San Diego + 1.858.314.1155

Connect:

Share

Meredith Stewart represents biotechnology and pharmaceutical clients in patent disputes. She has practiced in contested cases in federal district court and at the Patent Trial and Appeal Board (PTAB).

Meredith has experience through the life cycle of patent cases, including pre-suit investigation, pleadings, and fact and expert discovery. She has drafted various briefs and motions, including claim construction and case dispositive briefs. Meredith also has worked extensively with expert witnesses, including drafting expert reports.

Before joining Jones Day, Meredith served as a law clerk to Judge Todd M. Hughes of the United States Court of Appeals for the Federal Circuit and as a judicial intern for Judge Cheri Beasley, former Chief Justice of the Supreme Court of North Carolina.

During law school, Meredith received the Faculty Award for Intellectual Property and Technology and was a Margolis Scholar at the Duke-Margolis Center for Health Policy. She also conducted an independent study on the U.S. Food & Drug Administration's evolving regulation of artificial intelligence (AI) medical devices.

Prior to practicing law, Meredith earned her master of public health at the University of North Carolina at Chapel Hill and worked in health care for several years.

Experience

  • Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against SandozJones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.
  • Puma Biotechnology asserts patent infringement claims against AstraZeneca's Tagrisso® (osimertinib) products for treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancerJones Day is representing Puma Biotechnology, Inc. in a patent infringement action against defendants for infringement of United States Patent Nos. 10,603,314 and 10,596,162.
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.